Compounding Legislation’s Rationale Gets Boost From GAO – But Its Details Don’t
This article was originally published in The Pink Sheet Daily
Executive Summary
A report from the federal watchdog agency backs up FDA’s quest for legislative action, but makes no specific recommendations on how to improve the agency’s capabilities to regulate compounding pharmacies.